[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
This clinical trial studies how well 18F-fluoromisonidazole ([18F]FMISO) positron emission tomography (PET)/computed tomography (CT) works after transcatheter arterial embolization in imaging tumors in patients with liver cancer. Transcatheter arterial embolization blocks blood flow to tumor cells by inserting tiny foreign particles into an artery near the tumor. [18F]FMISO is a type of radioimaging agent that binds to large molecules in tumor cells that have a low level of oxygen, and the radiation given off by [18F]FMISO is picked up by a PET scan and this may help researchers learn whether changes occur in the tumors after treatment, which can help decide how well the treatment worked earlier than is currently possible
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- procedure: Arterial Embolization
- drug: 18F-Fluoromisonidazole
- diagnostic test: Computed Tomography
- diagnostic test: Positron Emission Tomography
Eligibility
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Histopathologic or imaging and clinical features of tumor(s) diagnostic for
hepatocellular carcinoma with at least one tumor >= 1.5 cm; imaging features
diagnostic for hepatocellular carcinoma will be defined as Liver Imaging Reporting and
Data System (LIRADS) 4 or greater
- Total bilirubin < 3.0
- Child Pugh A or B
- Tumor amenable to transcatheter arterial embolization
- Able to provide informed consent
Exclusion Criteria:
- Uncontrolled large ascites
- Main or segmental portal vein thrombosis
- Locoregional treatment of hepatocellular carcinoma within the prior 3 months or
chemotherapy within the previous 3 months
- Inability or contraindication to undergo transcatheter arterial embolization
- Inability to lay flat for at least 2 consecutive hours
- Severe acute illness
- Uncontrolled chronic illness such as hypertension, diabetes, or heart failure
- Contraindication to CT or MRI contrast
- Pregnancy
Ages Eligible for Study
19 Years - N/A
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
CCTO
650-498-7061
Not Recruiting